CR20120642A - Lactamas sustituidas con piperidinilo como moduladores de gpr119 - Google Patents
Lactamas sustituidas con piperidinilo como moduladores de gpr119Info
- Publication number
- CR20120642A CR20120642A CR20120642A CR20120642A CR20120642A CR 20120642 A CR20120642 A CR 20120642A CR 20120642 A CR20120642 A CR 20120642A CR 20120642 A CR20120642 A CR 20120642A CR 20120642 A CR20120642 A CR 20120642A
- Authority
- CR
- Costa Rica
- Prior art keywords
- gpr119
- modulators
- readers
- piperidinyl
- replaced
- Prior art date
Links
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 title abstract 2
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 title abstract 2
- -1 PIPERIDINYL Chemical class 0.000 title 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Compuestos de la Fórmula I: y sales farmacéuticamente de ellos, en donde X1, X2, L, R3, R4, R5, R6, R6a, R7, R9, R9a, y n tienen las definiciones que se dieron en la memoria descriptiva, son moduladores de GPR119 y son útiles en el tratamiento o la prevención de enfermedades tales como, en forma no taxativa, diabetes tipo 2, complicaciones diabéticas, síntomas de la diabetets, síndrome metabólico, obesidad, dislipidemia y condiciones relacionadas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34546110P | 2010-05-17 | 2010-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20120642A true CR20120642A (es) | 2013-03-11 |
Family
ID=44584599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20120642A CR20120642A (es) | 2010-05-17 | 2012-12-17 | Lactamas sustituidas con piperidinilo como moduladores de gpr119 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8754226B2 (es) |
| EP (1) | EP2571864A1 (es) |
| JP (1) | JP2013530947A (es) |
| KR (1) | KR20130113948A (es) |
| CN (1) | CN103080101A (es) |
| AR (1) | AR081197A1 (es) |
| AU (1) | AU2011256455A1 (es) |
| BR (1) | BR112012029395A2 (es) |
| CA (1) | CA2799779A1 (es) |
| CL (1) | CL2012003211A1 (es) |
| CO (1) | CO6670520A2 (es) |
| CR (1) | CR20120642A (es) |
| IL (1) | IL223092A0 (es) |
| MX (1) | MX2012013465A (es) |
| PH (1) | PH12012502255A1 (es) |
| RU (1) | RU2012154308A (es) |
| SG (1) | SG185615A1 (es) |
| TW (1) | TW201141849A (es) |
| UY (1) | UY33392A (es) |
| WO (1) | WO2011146335A1 (es) |
| ZA (1) | ZA201209605B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011256455A1 (en) | 2010-05-17 | 2013-01-10 | Array Biopharma Inc. | Piperidinyl-substituted lactams as GPR119 modulators |
| KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| KR101415742B1 (ko) * | 2011-12-21 | 2014-07-04 | 영남대학교 산학협력단 | 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물 |
| CA2878625A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| EP2892897A1 (en) * | 2012-09-05 | 2015-07-15 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
| AR092924A1 (es) | 2012-10-09 | 2015-05-06 | Sanofi Sa | Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| JP2016527193A (ja) * | 2013-06-07 | 2016-09-08 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換トリアゾロピリジン |
| AR099937A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| EP3126346B1 (en) * | 2014-04-04 | 2018-07-11 | Sanofi | Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
| AR099936A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
| US20170342304A1 (en) | 2015-01-19 | 2017-11-30 | Fujimi Incorporated | Polishing composition |
| US11499070B2 (en) | 2015-01-19 | 2022-11-15 | Fujimi Incorporated | Modified colloidal silica and method for producing the same, and polishing agent using the same |
| JP2019504010A (ja) | 2015-12-17 | 2019-02-14 | シンジェンタ パーティシペーションズ アーゲー | 殺微生物オキサジアゾール誘導体 |
| AR110988A1 (es) | 2017-02-21 | 2019-05-22 | Sanofi Sa | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CR20220644A (es) | 2020-06-22 | 2023-02-17 | Hoffmann La Roche | Derivados de sulfona |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| CN114539073A (zh) * | 2022-02-18 | 2022-05-27 | 郑州萃智医药科技有限公司 | 3-溴-2-氯-4,6-二氟苯胺的合成方法 |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
| CN120476107A (zh) | 2022-12-15 | 2025-08-12 | 先正达农作物保护股份公司 | 可用作杀有害生物剂的新型的二环-甲酰胺化合物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| JP4958560B2 (ja) | 2003-12-24 | 2012-06-20 | プロシディオン・リミテッド | Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体 |
| CN101090885A (zh) | 2004-02-23 | 2007-12-19 | 塔夫茨大学信托人 | 作为构象限定的肽模拟物抑制剂的内酰胺类化合物 |
| TW200610761A (en) | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
| EA011671B1 (ru) | 2004-06-04 | 2009-04-28 | Арена Фармасьютикалз, Инк. | Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств |
| AU2005309826A1 (en) * | 2004-11-22 | 2006-06-01 | Merck & Co., Inc. | Piperidinyl piperidine tachykinin receptor antagonists |
| US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| US20090264650A1 (en) * | 2005-03-31 | 2009-10-22 | Nobuo Cho | Prophylactic/Therapeutic Agent for Diabetes |
| TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| BRPI0612599A2 (pt) | 2005-06-30 | 2010-11-23 | Prosidion Ltd | composto, composição farmacêutica compreendendo o mesmo, método de tratamento e uso do mesmo |
| EP1910290A2 (en) | 2005-06-30 | 2008-04-16 | Prosidion Limited | Gpcr agonists |
| US20080025795A1 (en) * | 2006-07-28 | 2008-01-31 | Cliff Purnell | Methods, apparatus and system for drain tiles |
| US20080103123A1 (en) | 2006-08-30 | 2008-05-01 | Biovitrum | New compounds |
| CA2672307A1 (en) | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Bipiperidinyl compounds, compositions containing such compounds and methods of treatment |
| AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| ATE557024T1 (de) | 2008-07-10 | 2012-05-15 | Prosidion Ltd | Piperidinverbindungen als gpcr-agonisten |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| PT2473049T (pt) * | 2009-09-04 | 2019-03-04 | Sunesis Pharmaceuticals Inc | Inibidores de tirosina quinase de bruton |
| AU2011237775A1 (en) | 2010-04-06 | 2012-11-22 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| AU2011256455A1 (en) | 2010-05-17 | 2013-01-10 | Array Biopharma Inc. | Piperidinyl-substituted lactams as GPR119 modulators |
| US20130184257A1 (en) | 2010-09-17 | 2013-07-18 | Thomas Daniel Aicher | Piperidinyl-substituted lactams as gpr119 modulators |
| US20140256756A1 (en) | 2011-11-03 | 2014-09-11 | Array Biopharma Inc. | Piperidinyl-substituted lactams as gpr119 modulators |
| WO2013074641A1 (en) | 2011-11-16 | 2013-05-23 | Array Biopharma Inc. | Piperidinyl- substituted cyclic ureas as gpr119 modulators |
-
2011
- 2011-05-13 AU AU2011256455A patent/AU2011256455A1/en not_active Abandoned
- 2011-05-13 BR BR112012029395A patent/BR112012029395A2/pt not_active IP Right Cessation
- 2011-05-13 CN CN2011800291586A patent/CN103080101A/zh active Pending
- 2011-05-13 PH PH1/2012/502255A patent/PH12012502255A1/en unknown
- 2011-05-13 RU RU2012154308/04A patent/RU2012154308A/ru not_active Application Discontinuation
- 2011-05-13 SG SG2012084471A patent/SG185615A1/en unknown
- 2011-05-13 CA CA2799779A patent/CA2799779A1/en not_active Abandoned
- 2011-05-13 JP JP2013511238A patent/JP2013530947A/ja not_active Withdrawn
- 2011-05-13 US US13/698,257 patent/US8754226B2/en not_active Expired - Fee Related
- 2011-05-13 WO PCT/US2011/036443 patent/WO2011146335A1/en not_active Ceased
- 2011-05-13 MX MX2012013465A patent/MX2012013465A/es not_active Application Discontinuation
- 2011-05-13 KR KR1020127032867A patent/KR20130113948A/ko not_active Withdrawn
- 2011-05-13 EP EP11754769A patent/EP2571864A1/en not_active Withdrawn
- 2011-05-17 TW TW100117276A patent/TW201141849A/zh unknown
- 2011-05-17 UY UY0001033392A patent/UY33392A/es not_active Application Discontinuation
- 2011-05-17 AR ARP110101683A patent/AR081197A1/es unknown
-
2012
- 2012-11-16 CL CL2012003211A patent/CL2012003211A1/es unknown
- 2012-11-18 IL IL223092A patent/IL223092A0/en unknown
- 2012-12-17 CO CO12228271A patent/CO6670520A2/es not_active Application Discontinuation
- 2012-12-17 CR CR20120642A patent/CR20120642A/es unknown
- 2012-12-18 ZA ZA2012/09605A patent/ZA201209605B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2571864A1 (en) | 2013-03-27 |
| RU2012154308A (ru) | 2014-06-27 |
| BR112012029395A2 (pt) | 2016-07-26 |
| CO6670520A2 (es) | 2013-05-15 |
| KR20130113948A (ko) | 2013-10-16 |
| ZA201209605B (en) | 2014-05-28 |
| TW201141849A (en) | 2011-12-01 |
| US8754226B2 (en) | 2014-06-17 |
| CL2012003211A1 (es) | 2013-04-26 |
| SG185615A1 (en) | 2012-12-28 |
| IL223092A0 (en) | 2013-02-03 |
| UY33392A (es) | 2012-11-30 |
| JP2013530947A (ja) | 2013-08-01 |
| CN103080101A (zh) | 2013-05-01 |
| WO2011146335A1 (en) | 2011-11-24 |
| CA2799779A1 (en) | 2011-11-24 |
| PH12012502255A1 (en) | 2013-02-04 |
| AU2011256455A1 (en) | 2013-01-10 |
| AR081197A1 (es) | 2012-07-04 |
| MX2012013465A (es) | 2013-12-02 |
| US20130158009A1 (en) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20120642A (es) | Lactamas sustituidas con piperidinilo como moduladores de gpr119 | |
| UY33614A (es) | Lactamas sustituidas por piperidinilo como moduladores de gpr119 | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CU20140025A7 (es) | Pirimidinas anilladas sustituidas | |
| BR112013002957A2 (pt) | composto de 1,4,5,6-tetrahidro-pirimidin-2-ilamina | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| CO6440531A2 (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
| CR20110658A (es) | Antagonistas de la trayectoria hedgehog de ftalazina desustituida | |
| CL2013003025A1 (es) | Compuestos derivados de pirimidinas de diaminocarboxamida y diaminocarbonitrilo, como inhibidores de quinasa jnk; composicion farmaceutica; metodo de inhibicion in vitro; y su uso en el tratamiento o prevencion de trastornos fibroticos del higado, diabetes o sindrome metabolico conduciendo a trastornos fibroticos del higado. | |
| EA201270824A1 (ru) | Соединения для уменьшения продукции бета-амилоида | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| EA201201648A1 (ru) | Стимуляторы sgc | |
| CL2009000402A1 (es) | Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras. | |
| EA201590296A1 (ru) | Дейтерированный ибрутиниб | |
| AR077642A1 (es) | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo | |
| GT201200293A (es) | Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs) | |
| MX349254B (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| BR112012027197A2 (pt) | combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas | |
| EP2678420A4 (en) | AUTOTROPHE HYDROGEN BACTERIA AND USES THEREOF | |
| EP2663576A4 (en) | NEW WNT COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF SUCH COMPOSITIONS | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| BR112012030482A2 (pt) | tratamento de diabetes tipo 2 | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
| EA201391586A1 (ru) | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ | |
| MA32461B1 (fr) | Dronedarone pour la prevention de cardioversion |